Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Revenue (2016 - 2025)

Historic Revenue for Marker Therapeutics (MRKR) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Marker Therapeutics' Revenue fell 3598.52% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 12723.94%. This contributed to the annual value of $200000.0 for FY2024, which is 9395.98% down from last year.
  • Per Marker Therapeutics' latest filing, its Revenue stood at $1.2 million for Q3 2025, which was down 3598.52% from $861184.0 recorded in Q2 2025.
  • Marker Therapeutics' Revenue's 5-year high stood at $2.5 million during Q1 2023, with a 5-year trough of -$4.1 million in Q4 2024.
  • Its 4-year average for Revenue is $770955.3, with a median of $964322.0 in 2022.
  • Data for Marker Therapeutics' Revenue shows a peak YoY increase of 64766.12% (in 2024) and a maximum YoY decrease of 49178.34% (in 2024) over the last 5 years.
  • Marker Therapeutics' Revenue (Quarter) stood at $759143.0 in 2022, then soared by 39.17% to $1.1 million in 2023, then crashed by 491.78% to -$4.1 million in 2024, then skyrocketed by 129.79% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $861184.0 for Q2 2025, and $349104.0 during Q1 2025.